Oppenheimer Issues a Buy Rating on Oric Pharmaceuticals (ORIC)

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Oric Pharmaceuticals (ORIC) yesterday and set a price target of $52.00. The company’s shares closed last Thursday at $23.87.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 42.8% and a 48.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Rocket Pharmaceuticals, and Sensei Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oric Pharmaceuticals with a $50.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $40.81 and a one-year low of $18.60. Currently, Oric Pharmaceuticals has an average volume of 229.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts